CellCarta

Spatial biology generates some of the richest data in translational research, but only when the analysis framework can keep up.

That's why we built our platform-agnostic mIF analysis framework, SPARTA: Spatial Phenotyping and Analysis in Regions of Tissue with AI.

Developed by our histopathology team, SPARTA is designed to standardize and accelerate how multiplex immunofluorescence datasets are processed, across imaging systems, across sites, and across programs, to ensure we generate interpretable, reproducible mIF data that can move biomarker programs forward with confidence.

Read the full CellTalk article by Yannick Waumans, our Executive Director of Histopathology Operations, and discover how SPARTA is changing how we turn spatial biology data into decisions.

🔗https://buff.ly/OQYhhTM

Press Release: CellCarta and Leica Biosystems are expanding their proven companion diagnostic (CDx) joint development model to biopharma sponsors worldwide.

Built on operational success in China, this partnership introduces a flexible, end-to-end CDx development framework that aligns assay development, clinical trial ex*****on, regulatory strategy, and commercial kit planning within a single coordinated model, while accommodating diverse regulatory pathways.

The result: a lower-risk, more streamlined path from early-stage assay to global CDx commercialization.

The partnership also leverages the integration of advanced digital pathology, combining Leica Biosystems' Aperio Scanners, IMS platform and expanding AI-enabled ecosystem with CellCarta's globally standardized digital pathology infrastructure for clinical trials.

Read the full announcement: https://buff.ly/iRwhnEL